South Korea
· Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 86.86 billion. The enterprise value is 93.23 billion.
| Market Cap | 86.86B |
| Enterprise Value | 93.23B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 76.87 million shares outstanding. The number of shares has increased by 7.73% in one year.
| Shares Outstanding | 76.87M |
| Shares Change (YoY) | +7.73% |
| Shares Change (QoQ) | +15.06% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | n/a |
| Float | 47.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.71 |
| PB Ratio | 4.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.87 |
| EV / Sales | 3.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -19.42 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.48 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.30 |
| Interest Coverage | -4.06 |
Financial Efficiency
Return on equity (ROE) is -25.07% and return on invested capital (ROIC) is -6.51%.
| Return on Equity (ROE) | -25.07% |
| Return on Assets (ROA) | -5.03% |
| Return on Capital (ROIC) | -6.51% |
| Revenue Per Employee | 962.39M |
| Profits Per Employee | -147.02M |
| Employee Count | 29 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.53% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +30.53% |
| 50-Day Moving Average | 1,103.66 |
| 200-Day Moving Average | 1,180.71 |
| Relative Strength Index (RSI) | 53.74 |
| Average Volume (20 Days) | 123,932 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 27.91 billion and -4.26 billion in losses. Loss per share was -63.62.
| Revenue | 27.91B |
| Gross Profit | 8.55B |
| Operating Income | -3.48B |
| Pretax Income | -4.29B |
| Net Income | -4.26B |
| EBITDA | -1.62B |
| EBIT | -3.48B |
| Loss Per Share | -63.62 |
Balance Sheet
The company has 9.46 billion in cash and 15.83 billion in debt, giving a net cash position of -6.37 billion or -82.92 per share.
| Cash & Cash Equivalents | 9.46B |
| Total Debt | 15.83B |
| Net Cash | -6.37B |
| Net Cash Per Share | -82.92 |
| Equity (Book Value) | 19.65B |
| Book Value Per Share | 256.18 |
| Working Capital | 7.01B |
Cash Flow
In the last 12 months, operating cash flow was -4.37 billion and capital expenditures -425.93 million, giving a free cash flow of -4.80 billion.
| Operating Cash Flow | -4.37B |
| Capital Expenditures | -425.93M |
| Free Cash Flow | -4.80B |
| FCF Per Share | -62.45 |
Margins
Gross margin is 30.64%, with operating and profit margins of -12.47% and -15.28%.
| Gross Margin | 30.64% |
| Operating Margin | -12.47% |
| Pretax Margin | -15.37% |
| Profit Margin | -15.28% |
| EBITDA Margin | -5.82% |
| EBIT Margin | -12.47% |
| FCF Margin | -17.20% |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.73% |
| Shareholder Yield | -7.73% |
| Earnings Yield | -5.63% |
| FCF Yield | -5.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 1.65. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | n/a |